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Abstract We have identified a novel 3845 bp cDNA differen-
tially expressed in a human melanoma metastasis model.
Northern blot analysis showed expression in the poorly and
intermediately metastasizing cell lines and a marked down-
regulation in the highly metastatic cell lines. Using RT-PCR
expression was also seen in several other tumor cell lines and
normal cell types of human origin. cDNA sequence analysis
revealed an ORF of 687 amino acids containing seven putative
transmembrane domains C-terminally and a long N-terminus.
The gene was mapped to 16q13. Highest homology was observed
with members of the EGF-TM7 subfamily of the secretin/
calcitonin receptor family. We propose the delineation of a
subfamily of TM7 proteins, LN-TM7, containing seven trans-
membrane proteins with a long N-terminal extracellular part.
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1. Introduction
Several genes or gene products have been identi¢ed which
are di¡erentially expressed during melanocytic tumor progres-
sion [1]. To identify di¡erentially expressed genes various
methods have been used at the DNA, mRNA and protein
levels. Among the strategies used di¡erential hybridization,
subtractive hybridization, mRNA di¡erential display and se-
rial analysis of gene expression [2] are the most common. In
oncobiology these techniques have been successfully used in
the identi¢cation and subsequent isolation of di¡erentially ex-
pressed genes in several types of tumors [3^10]. To pick up
possible human melanocytic tumor progression markers we
performed mRNA di¡erential display [11], comparing two
human melanoma cell lines: 1F6 and a spontaneous mutant
of this cell line, 1F6m. Whereas 1F6 only sporadically gives
rise to metastases after s.c. inoculation into nude mice, 1F6m
metastasizes very frequently and quickly [12].
Here we describe a new cDNA, TM7XN1, which inversely
correlates with the metastatic potential in a panel of human
melanoma cell lines. Sequence analysis and database searching
showed highest homology to members of the EGF-TM7 (sev-
en transmembrane molecules containing epidermal growth
factor-like domains) subfamily of the secretin peptide hor-
mone receptor family [13]. Based on extensive sequence and
homology searching, we argue for the delineation of a novel
subfamily of seven transmembrane receptors, named LN-TM7
(long N-terminus), including the novel TM7XN1 and the
EGF-TM7 molecules.
2. Materials and methods
2.1. Melanoma cell lines
Twenty-three human melanoma cell lines were used. A panel of
eight melanoma cell lines containing 530, 1F6, MV1, M14, Mel57,
BLM, MV3, and 1F6m was described earlier [12]. In this panel of
cell lines 530 and 1F6 are poorly metastatic, while MV3 and BLM are
highly metastatic cell lines. MV1, M14, and Mel57 are cell lines with
an intermediate metastatic capacity. 1F6m, a metastatic subline of
1F6, can be placed between the intermediate and highly metastatic
cell lines. All other human melanoma and non-melanoma cell lines
used are listed in Table 1 [12,14^20].
All cell lines were grown in Dulbecco’s modi¢ed Eagle’s medium as
described earlier [14]. Cultured pericytes, smooth muscle cells and
endothelial cells were a kind gift from Dr. M. Verbeek [21]. Cell
line U2OS and dendritic cells were a generous gift from Dr. F.
Hartgers (Department of Tumor Immunology, Academical Hospital
Nijmegen, The Netherlands). Keratinocytes, melanocytes and nevus
cells were cultured as described previously [22]. Fibroblasts were
grown on Eagle’s minimum essential medium (BioWhittaker, Wal-
kersville, MD, USA) supplemented with 20% human serum, 10% fetal
calf serum, and antibiotics.
2.2. Human tissues
Lesions from all stages of melanocytic tumor progression (common
nevi, atypical nevi, primary melanoma and melanoma metastases)
were excised from patients at the University Hospital Nijmegen,
The Netherlands. As normal human tissues we used disease-free sam-
ples from surgically removed tissues or from autopsies with post-mor-
tem delays shorter than 4 h. Tissue samples were snap-frozen in liquid
nitrogen and stored at 380‡C until use.
2.3. RNA isolation
From cultured cells total RNA was isolated using the RNeasy kit
(Qiagen, Hilden, Germany) following the manufacturer’s protocol.
From tissue samples total RNA was isolated (following the manufac-
turer’s protocol) by disrupting about 25 frozen sections of 20 Wm
thickness in 1 ml RNAzol B (Campro, Veenendaal, The Netherlands)
using a pestle. The RNAzol B method was followed by an additional
RNeasy cleaning step of the RNA.
2.4. mRNA di¡erential display
Before starting di¡erential display PCR, DNase I treatment was
performed on the RNA samples using the Message-Clean kit (Gen-
Hunter Corporation, Brookline, MA, USA). For di¡erential display
the RNAmap protocol (GenHunter) was used with some minor mod-
i¢cations. Di¡ering from the original protocol, we used [32P]dATP
instead of [35S]dATP. For the PCR, combinations of the four
T12MN primers together with six arbitrary primers, AP1;2;6;7;11;12
[23], were used.
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2.5. Northern blot analysis
Total RNA (10 Wg) was treated with glyoxal/DMSO or with form-
aldehyde [24], separated on a 1.2% agarose gel and blotted onto a
Hybond N membrane (Amersham, Aylesbury, UK). cDNA probes
were radiolabeled by [32P]dATP incorporation using a random-primed
DNA labeling kit (Roche Diagnostics GmbH, Penzberg, Germany).
Membranes were hybridized overnight with the radiolabeled probes at
65‡C in a hybridization mix (0.25 M sodium phosphate bu¡er pH 7.2,
7% SDS, 1% BSA, 1 mM EDTA, 0.1 mg/ml single stranded salmon
sperm DNA). Afterwards membranes were washed at 65‡C with wash
bu¡ers containing decreasing amounts of salt (1% SDS, 1 mM EDTA
and 0.25^0.05 M sodium phosphate pH 7.2), and autoradiographed
using Kodak Xomat-S ¢lms.
2.6. cDNA library screening, sequencing and homology searching
cDNA probes were labeled as described before and hybridized [24]
to a VZAP cDNA library of human melanoma cell line 530, kindly
provided by Dr. G. Swart, Department of Biochemistry, University of
Nijmegen, The Netherlands. After isolation of the full length cDNA,
sequencing on both strands was performed by Roche Diagnostics
GmbH, Penzberg, Germany. Homology searches were performed us-
ing BLAST [25] and software on all kinds of public servers of DNA
and protein databases on Internet (http://www.genome.ad.jp/;
http://www.ncbi.nlm.nih.gov/; http://expasy.hcuge.ch/;
http://dot.imgen.bcm.tmc.edu:9331/; http://www.genome.wi.mit.edu/).
2.7. RT-PCR
Synthesis of cDNA (10 min at 25‡C, followed by 59 min at 42‡C)
was performed on 0.5^1.0 Wg of total RNA using the AMV RT kit
(Roche Diagnostics GmbH, Penzberg, Germany). The reaction mix-
ture was supplemented with 0.04 U of random hexadeoxynucleotide
primers, 2 Wl 25 mM MgCl2, 1 Wl 10 mM dNTPs, 1 Wl of RT bu¡er
(100 mM Tris-HCl pH 8.3, 500 WM KCl), 25 U RNasin, 10 U AMV
reverse transcriptase and water to a ¢nal volume of 10 Wl. For am-
pli¢cation one tenth of the cDNA was supplemented with 2.5 Wl of
PCR bu¡er (200 mM (NH4)2SO4, 750 mM Tris-HCl pH 9, 0.1%
Tween), 5 Wl 1 M dNTPs, 10 pmol of each primer, 2.5 Wl 15 mM
MgCl2, 0.15 U of Thermoperfectplus DNA polymerase (Integro,
Zaandam, The Netherlands) and water to a ¢nal volume of 25 Wl.
PCR conditions were 45 s at 94‡C, 1 min at 59‡C and 1 min 30 s at
72‡C for 30 cycles. These cycles were preceded by 3 min denaturation
at 94‡C and followed by a 5 min elongation step at 72‡C. Primer
combinations and PCR product lengths were: L2-microglobulin (136
bp): sense: 5P-CTCGCGCTACTCTCTCTTTCT-3P ; antisense: 5P-
TGTCGGATTGATGAAACCCAG-3P ; TM7XN1 cDNA (474 bp):
sense: 5P-CCATCTTTCTGGTGACGC-3P ; antisense: 5P-GAGCT-
GATGGGGAGCCTG-3P. DNA molecular weight markers were
from Roche Diagnostics GmbH, Penzberg, Germany.
2.8. Chromosomal localization
Chromosomal localization of the corresponding gene was deter-
mined by genomic PCR on a panel of hamster/human and mouse/
human hybrid cell lines [26]. DNA of these cell lines, each speci¢c for
one human chromosome, was kindly provided by Dr. A. Simons,
Department of Human Genetics, University Hospital Nijmegen, The
Netherlands. PCR conditions were the same as used for the cDNA
primer combinations described above. Intron spanning primers and
PCR product length were: TM7XN1 DNA (526 bp): sense: 5P-
GCTCTGTCTCTCGTGGTC-3P ; antisense: 5P-GCATGGTCCACA-
GTTCTTG-3P.
3. Results and discussion
3.1. Isolation and cloning of TM7XN1 cDNA
With mRNA di¡erential display, using primer combination
T12MG and AP7, we detected a 250 bp cDNA (clone 25)
abundantly present in 1F6 and almost absent in 1F6m (not
shown). Using this 250 bp cDNA clone as a probe a Northern
blot, containing RNA from a panel of human melanoma cell
lines with varying metastatic potential, revealed two bands at
4.2 kb and 1.0 kb (Fig. 1A). Marked expression of the 4.2 kb
transcript was only seen in the poorly and intermediately
metastatic cell lines 530, 1F6, MV1 and M14. No expression
could be detected in the highly metastatic cell lines MV3 and
BLM. Very weak expression was seen in 1F6m cells. To in-
vestigate the speci¢city of the 1.0 kb band we did Northern
blot analyses of one poorly (530), one intermediately (MV1)
and two highly (MV3, BLM) metastatic cell lines with three
di¡erent PCR probes throughout the full length cDNA. The
probes represented the N-terminal part of the open reading
frame (ORF) (bp 351^979), the seven transmembrane region
(bp 1878^2352) and the 3P-UTR (untranslated region) (bp
3339^3689). With all three probes we could no longer detect
the 1 kb band, while the 4.2 kb band showed the same ex-
pression pattern. As an example we show the results for the
probe corresponding to the 3P-UTR (Fig. 1B). From these
results we concluded that the 1 kb signal was a background
hybridization of clone 25, the 250 bp probe (corresponding to
the last part of the 3P-UTR and part of the poly-A tail). Using
the 250 bp cDNA clone as a probe we screened a VZAP
cDNA library of human melanoma cell line 530, in which
marked expression of the 4.2 kb transcript was detected on
Northern blot. We isolated a 3845 bp cDNA and sequenced
this clone (EMBL: AJ011001). The original 250 bp clone
matched completely with the 3P part of the full length
cDNA. A variable poly-A tail may be the explanation for
the di¡erence in length of the estimated 4.2 kb on Northern
and the 3845 bp cloned cDNA. The cDNA contains an ORF
resulting in a protein of 687 amino acids (Fig. 2) including
seven putative C-terminal transmembrane domains (aa 405^
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Table 1
Expression of TM7XN1 in human tumor cell lines, primary cell cultures and organ tissues determined by RT-PCRa
Strong Moderate Weak Negative
Melanoma
cell lines
1F6 [12]; 451Lu [19]; 518A2 [14]; 530 [12];
603 [14]; A375m*; A375p*; Bowes*;
M24met [14] ; Mel57 [12] ; MKR [20];
MV1 [12]; OCM1 [17]; OMM1 [18];
WM164 [19]
1F6m [12]; E10 [14];
M14 [12]; ZKR [20]
BLM [12];
BRO [16];
MV3 [12];
SK-Mel-28*
Other tumor
cell lines
A431*; CaCo2*; HT29 [15]; Molt4*;
Umscc2 [14]
Hep/G2 [15];
HT1080 [15]
U2OS [15] Daudi*; Jurkat*;
K562 [15]; U937 [15]
Primary cell
cultures
keratinocytes; nevus cells ; endothelial cells;
melanocytes
¢broblasts PBMCsb ; peri-
cytes; smooth
muscle cells
dendritic cells
Organ tissue kidney; prostate;
testis
bladder; brain;
lungs; thyroid
gland; uterus
bone marrow; colon; heart;
ileum; liver; lymph node;
pancreas; spleen; stomach
aAll samples had a positive control PCR (L2M).
bPBMC, peripheral blood mononuclear cells; *cell lines from the American Type Culture Collection (Rockville, MD).
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656) and an N-terminal signal peptide (aa 1^25). The protein has
a very high leucine and serine content of respectively 14.8 and
11.1%. Using MOTIFFINDER (http://www.motif.genome.
ad.jp) we found, besides several phosphorylation sites, seven
potential N-glycosylation sites in the N-terminal part. The
short C-terminus contains some phosphorylation sites and a
putative AMP binding domain (aa 675^686) which, together
with a potential tyrosine kinase phosphorylation site (aa 546)
between TM4 and TM5, may be indicative for interaction
with signalling components. It also has a microbodies C-ter-
minal targeting site (aa 685^687). This site is normally in-
volved in guidance of proteins towards single membraned
organelles. The PSORT II server (http://psort.nibb.ac.jp) pre-
dicted TM7XN1 to be present in the membrane of the endo-
plasmic reticulum or in the plasma membrane. Determination
of the speci¢c localization of TM7XN1 protein needs further
studies.
3.2. Homology search
Homology and domain searches revealed a perfect homol-
ogy with many human ESTs from several types of both nor-
mal and tumor tissues. No functional clues from homology to
known domains were found in the long N-terminal part. We
could place the gene in the secretin/calcitonin receptor family
because of its strong C-terminal homology, especially towards
members of the recently described EGF-TM7 subfamily [13]
and other non-classical TM7 proteins. Next to the 30% iden-
tity in the C-terminal seven transmembrane part it also had a
long N-terminal part, though it lacked the EGF-like domains
which characterize the EGF-TM7 family. Based on these ¢nd-
ing we named the molecule TM7XN1, in which the X repre-
sents the lack of known domains (no EGF-like domains) and
unclear function of the long N-terminal part of the protein.
3.3. TM7XN1 expression
Expression of TM7XN1 was tested on a great number of
human cell types and tumor cell lines using RT-PCR. On a
melanoma cell line panel with known metastatic behavior, we
found a clear expression in the poorly and intermediately
metastatic cell lines 530, 1F6, MV1 and Mel57 (Fig. 3). Ex-
pression in M14 and 1F6m was somewhat lower. Though
Northern blot was negative for MV3 and BLM (Fig. 1), using
the more sensitive RT-PCR we could detect some weak ex-
pression in these highly metastatic cell lines (Fig. 3). Expres-
sion in 1F6m is higher than we expected on the basis of the
expression detected with the more quantitative Northern blot.
We think this is due to instability of the 1F6m cell line, as the
RNA used for the RT-PCR was isolated from 1F6m cells of a
much later passage than the one used for di¡erential display
and Northern blot. Based on the Northern blot results with
the melanoma cell line panel TM7XN1 expression inversely
correlates with the metastatic potential after s.c. inoculation
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Fig. 2. Protein sequence of TM7XN1. Indicated are the signal pep-
tide (bold; arrow), potential glycosylation sites (arrowhead), cysteine
box (open box) and transmembrane regions (underlined).
Fig. 1. Northern blot analysis of clone 25 on a panel of human mel-
anoma cell lines with di¡erent metastatic capacity after subcutane-
ous inoculation into nude mice [12]. A: Glyoxal/DMSO blot hybrid-
ized with clone 25, the 250 bp di¡erential display cDNA. Lane 1:
530; lane 2: 1F6; lane 3: MV1; lane 4: M14; lane 5: MV3; lane
6: BLM; lane 7: 1F6m. B: Formaldehyde blot hybridized with
PCR fragment corresponding to the 3P-UTR (bp 3339^3689) of the
full length cDNA. Lane 1: 530; lane 2: MV1; lane 3: MV3; lane
4: BLM. C: 28S and 18S rRNA bands of ethidium-stained formal-
dehyde gel.
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into nude mice. RT-PCR on RNA isolated from correspond-
ing xenografts of the cell line panel matched completely with
the results of the cultured cells (not shown). RT-PCR results
on expression of TM7XN1 in a great number of other cul-
tured normal human cells and cell lines are shown in Table 1.
All other human melanoma cell lines showed TM7XN1 ex-
pression, being weak in only four of all melanoma cell lines
tested (MV3, SK-mel-28, BLM and its parental cell line
BRO). Most cell lines derived from other tumor types also
expressed TM7XN1. In primary cell cultures strong expres-
sion was observed in keratinocytes, melanocytes, nevus cells
and endothelial cells (Table 1), while weak expression was
found in ¢broblasts, smooth muscle cells, pericytes, and pe-
ripheral blood mononuclear cells. Dendritic cells (non-stimu-
lated) were negative. In normal human tissues clear expression
was seen in kidney, prostate and testis, weak expression in
bladder, brain, lungs, uterus and thyroid glands and no ex-
pression in bone marrow, colon, heart, ileum, liver, lymph
node, pancreas, spleen, and stomach. We also studied
TM7XN1 mRNA expression in fresh human melanocytic le-
sions with RT-PCR. TM7XN1 expression was detected in all
stages of melanocytic tumor progression (not shown). Since
not only melanocytic cells but also other cell types present in
these lesions (keratinocytes, ¢broblasts, endothelial cells) may
express TM7XN1 (see Table 1) we need additional studies to
determine whether there are di¡erences in expression between
melanocytic cells in the di¡erent stages of tumor progression.
For this purpose we are currently raising antibodies against
TM7XN1 to be able to study expression of the corresponding
protein at the single cell level.
Our data indicate that TM7XN1 is widely distributed and
expressed in a great number of both normal and tumor cells
and tissues. This ¢nding is in line with the perfect homology
of the gene with numerous human ESTs. Expression of the
best studied EGF-TM7 molecules (CD97 and EMR1) is
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Table 2
Characteristics of TM7XN1 homologues
Protein Species EMBL
accession
number
length
(aa)
Signal peptide
(aa)
N-terminus
(aa)
EGF
domain
cys-box Miscellaneous
domainsa
Ref.
Secretin rec. Calcitonin r. H. sapiens L00587 490 22 132 ^ 3 [29]
Secretin r. H. sapiens U20178 440 22 121 ^ 3 [30]
LN-TM7 TM7XN1 H. sapiens AJ011001 687 26 381 ^ + -
HE6 H. sapiens X81892 1014 37 587 ^ + [31]
Latrophilin R. norvegicus U78105 1466 24 831 ^ + [32]
KIAA0786* H. sapiens AB018329 s 1021 ^ s 410 ? + ? [33]
KIAA0768* H. sapiens AB018311 s 872 ^ s 290 ? + ? [33]
BAI-1 H. sapiens AB005297 1584 25 924 ^ + RGD;
TSP1 (5U)
[34]
BAI-2 H. sapiens AB005298 1572 23 900 ^ + extra TMs;
L-zipper;
TSP1 (5U)
[35]
BAI-3 H. sapiens AB005299 1522 24 855 ^ + TSP1 (5U) [35]
B0286.2 C. elegans U39848 1582 ^ 907 ^ + extra TM [36]
B0457.1 C. elegans Z54306 1014 29 522 ^ + [36]
F31D5.5 C. elegans U28941 1817 50 1473 ^ 3 RGD [36]
BOSS D. melano-
gaster
X55887 896 37 498 ^ 3 [37]
GRL101 L. stagnalis Z23104 1115 22 747 ^ 3 LDL-RA (12U) ;
LRR (6U)
[38]
EGF-TM7 CD97 H. sapiens X84700 742 20 440 3^5 + RGD [39]
EMR1 H. sapiens X81479 886 17 583 1^6 + [40]
KIAA-0279* H. sapiens D87469 2408 21 1842 6 + cadherin (4U) ;
L-zipper
[28]
CELSR1 M. musculus AF031572 3034 26 2459 7 + cadherin (7U) ;
laminin AG (2U)
[41]
R29368.2* H. sapiens AC004262 s 344 ^ s 58 ? + ? [42]
aRGD = Arg-Gly-Asp; TSP1 = thrombospondin type 1; TM = transmembrane; L-zipper = Leucine zipper; LDL-RA = low density lipoprotein class
A; LRR = leucine-rich repeats; cadherin = cadherin-like domain; laminin AG = laminin A G-domain.
*Only partial protein sequence known.
Fig. 3. A: Expression of TM7XN1 in human melanoma cell lines
with di¡erent metastatic potential using RT-PCR. Lane 1: DNA
molecular weight marker XIV (100 bp ladder); lane 2: water con-
trol; lane 3: 530; lane 4: 1F6; lane 5: MV1; lane 6: M14; lane 7:
Mel57; lane 8: 1F6m; lane 9: MV3; lane 10: BLM. B: L2-Micro-
globulin control RT-PCR.
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mainly seen in cells of the hematopoietic lineage and in solid-
tumor-derived cell lines [13]. They are described as leukocyte
antigens with a possible immunologic role. Recently CD97
expression has also been described in thyroid tumors [27].
As for CD97, expression in (para)thyroid tumors is also the
case for KIAA0279 (AA843289; EMBL), which like
TM7XN1 is mainly expressed in testis, brain, kidney, and
prostate [28].
3.4. Chromosomal localization
Inspection of the human gene map (NCBI) showed perfect
homology of TM7XN1 with an unidenti¢ed transcript. This
STS (sequence tagged site) was called STSG1704 and located
on 16q13 between microsatellite markers D16S419 and
D16S408 (65^72 cM). To con¢rm localization of TM7XN1
on chromosome 16, we performed an intron spanning PCR
on DNA of a human chromosome speci¢c hybrid cell panel
(hamster/human or mouse/human). We could only detect the
526 bp speci¢c product in the DNA sample of the chromo-
some 16 speci¢c hybrid cell line (not shown). Some EGF-TM7
molecules map on chromosome 19p13, indicating the position
of a EGF-TM7 gene cluster on the short arm of chromosome
19.
3.5. Alignment: LN-TM7
To get more insight into the relationship between
TM7XN1, the secretin-like receptors and EGF-TM7 mole-
cules, we compared TM7XN1 with several other family mem-
FEBS 21698 15-3-99
Fig. 4. Multiple protein alignment of the cys-box and the transmembrane regions of the secretin receptor (white), LN-TM7 family members
(light gray), and EGF-TM7 family members (gray). Strongly conserved amino acid residues are boxed and bold; frequently homologues resi-
dues are only boxed. Gaps (-) are introduced to allow maximal alignment. * only partial protein is known.
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bers that were found previously and with other proteins that
we additionally found during homology searches with parts of
TM7XN1 (Table 2) [29^42]. Some proteins of non-human
origin were used when no human homologue was known.
All sequences aligned have seven C-terminal transmembrane
domains. The proteins vary markedly in length, with the se-
cretin and calcitonin receptors (G-protein-coupled receptor
family 2) being the smallest. These peptide hormone receptors
have a relatively short N-terminus (6 200 aa), containing
their hormone binding domain. The recently described
EGF-TM7 subfamily members have a much longer extracel-
lular part containing several EGF-like domains [13]. Several
splice variants of the EGF-TM7 molecules with variable num-
bers of EGF-like domains have been reported [43]. Our
TM7XN1 protein is very homologous to the secretin receptor
and to CD97 and EMR1, but lacks any known domain in its
long N-terminus. In Table 2 we have made a separation be-
tween EGF-TM7 members and molecules with a long N-ter-
minus lacking EGF-like domains, LN-TM7. Their N-terminus
is longer than 300 bp and most proteins contain a so-called
cysteine box (cys-box): C-x14ÿ24-C-x11-C-x-C [31]. Cleavable
signal peptides were found in all proteins of which the start of
translation is known [44], except for B0286.2. Additional
EGF-TM7 molecules are the human KIAA0279 and
R29368.2 as well as mouse CELSR1. Because R29368.2 has
50% identity with EMR1 and because the gene is located on
19p13, as are CD97 and EMR1, we suspect this gene to be an
EGF-TM7 family member. KIAA0279 is not located on chro-
mosome 19p13, but on chromosome 1 [28], while CELSR1
was mapped to human 22qter [41].
Instead of EGF-like domains some of the LN-TM7 mole-
cules possess other known domains (Table 2) in their long N-
terminus. These putative dual-function proteins are believed
to be formed by genetic rearrangements, like exon shu¥ing,
by which TM7 proteins gained additional domains from other
genes [45^47]. Almost all LN- and EGF-TM7 molecules have
a highly glycosylated mucin-like region within their N-termi-
nal extracellular part between the membrane-spanning do-
main and the N-terminal conformational domain(s). This re-
gion is often lacking cysteine residues. It was already
postulated that the long N-termini capture a ligand and
then present this ligand to the binding pocket situated inside
the TM7 structure. The peptide hormone receptors do not
need such a long N-terminus because of the small peptide
ligand [38].
Fig. 4 shows an alignment of the seven transmembrane
domains and the cys-box preceding the ¢rst membrane do-
main of some representatives of the subfamilies investigated.
All proteins have the characteristic conserved cysteines in
loops 2 and 4 (data not shown) which are thought to be
necessary for stabilization of the transmembranal conforma-
tion of G-protein-coupled receptors [48]. From the alignment
of the cysteine box a LN-TM7 speci¢c protein consensus se-
quence for the cys-box can be distilled: C-x2-W-x6ÿ16-W-x4-C-
x11-C-x-C. Next to the consensus described earlier [31], some
very highly conserved tryptophan residues are also present.
Some less well-conserved but very frequent amino acids,
such as the FAVLM sequence in the last part of the cys-
box, are also indicated in Fig. 4. Based on the comparisons
we argue for the delineation of a novel LN-TM7 subfamily of
the secretin receptor family. For most members there is no
experimental evidence for G-protein coupling. Only latrophi-
lin has been shown to be linked to G-proteins (GK0) and
inositol polyphosphate production [32,49]. Since TM7XN1
does not have any known speci¢c functional domain with
regard to a possible ligand structure, all re£ections about its
function are speculative. However, if TM7XN1, like CD97
[50], should function as an adhesion molecule, downregulation
as seen in the most aggressive melanoma cell lines might ex-
plain its involvement in the metastatic capacity of these tumor
cells.
3.6. Summary
TM7XN1 is a novel protein placed in a novel LN-TM7
family of seven transmembrane proteins, probably G-pro-
tein-coupled, with long N-terminal domains. These domains
are presented to the environment by a long rod-like glycosyl-
ated spacer. The whole extracellular domain seems to be car-
ried and stabilized by a cysteine box, serving as a statue foot
on top of the seven transmembrane anchor. Although we
found a marked downregulation of TM7XN1 expression in
the highly metastatic melanoma cell lines, a possible role of
TM7XN1 in melanocytic tumor progression needs further
studies which are in progress now.
Acknowledgements: We would like to acknowledge Dr. T. Wobbes
(Department of Surgery, University Hospital Nijmegen) and Dr. M.
de Rooij (Department of Dermatology, University Hospital Nijme-
gen) for providing fresh surgical specimens. We thank Dr. G. Swart
(Department of Biochemistry, University of Nijmegen) for providing
the cDNA library of human melanoma cell line 530. Dr. M. Herlyn
(The Wistar Institute, Philadelphia, PA, USA) is acknowledged for
providing cell lines 451Lu and WM164. For generously supplying cell
lines MKR and ZKR we thank Dr. U. Keilholz (Department of In-
ternal Medicine, University of Berlin, Berlin, Germany). We thank
Dr. F. Hartgers (Department of Tumor Immunology, University Hos-
pital Nijmegen) who supplied us with RNA of dendritic cells and cell
line U2OS, and Dr. A. Simons (Department of Human Genetics,
University Hospital Nijmegen) who generously provided DNA from
human chromosome speci¢c somatic hybrid cells.
References
[1] Weterman, M.A., van Muijen, G.N., Bloemers, H.P. and Ruiter,
D.J. (1994) Lab. Invest. 70, 593^608.
[2] Velculescu, V.E., Zhang, L., Vogelstein, B. and Kinzler, K.W.
(1995) Science 270, 484^487.
[3] Shen, R., Su, Z.Z., Olsson, C.A. and Fisher, P.B. (1995) Proc.
Natl. Acad. Sci. USA 92, 6778^6782.
[4] Lee, J.H. and Welch, D.R. (1997) Int. J. Cancer 71, 1035^1044.
[5] Zhang, L., Zhou, W., Velculescu, V.E., Kern, S.E., Hruban,
R.H., Hamilton, S.R., Vogelstein, B. and Kinzler, K.W. (1997)
Science 276, 1268^1272.
[6] van Groningen, J.J., Bloemers, H.P. and Swart, G.W. (1995)
Cancer Res. 55, 6237^6243.
[7] Yeatman, T.J. and Mao, W. (1995) Nucleic Acids Res. 23, 4007^
4008.
[8] Jiang, H., Lin, J.J., Su, Z.Z., Goldstein, N.I. and Fisher, P.B.
(1995) Oncogene 11, 2477^2486.
[9] Francia, G., Mitchell, S.D., Moss, S.E., Hanby, A.M., Marshall,
J.F. and Hart, I.R. (1996) Cancer Res. 56, 3855^3858.
[10] Duncan, L.M., Deeds, J., Hunter, J., Shao, J., Holmgren, L.M.,
Woolf, E.A., Tepper, R.I. and Shyjan, A.W. (1998) Cancer Res.
58, 1515^1520.
[11] Liang, P. and Pardee, A.B. (1992) Science 257, 967^971.
[12] Westphal, J.R., van’t Hullenaar, R.G., van der Laak, J.A., Cor-
nelissen, I.M., Schalkwijk, L.J., van Muijen, G.N., Wesseling, P.,
de Wilde, P.C., Ruiter, D.J. and de Waal, R.M. (1997) Br. J.
Cancer 76, 561^570.
[13] McKnight, A.J. and Gordon, S. (1996) Immunol. Today 17, 283^
287.
FEBS 21698 15-3-99
A.J.W. Zendman et al./FEBS Letters 446 (1999) 292^298 297
[14] de Vries, T.J., Fourkour, A., Wobbes, T., Verkroost, G., Ruiter,
D.J. and van Muijen, G.N.P. (1997) Cancer Res. 57, 3223^
3229.
[15] Quax, P.H., van Leeuwen, R.T., Verspaget, H.W. and Verheijen,
J.H. (1990) Cancer Res. 50, 1488^1494.
[16] Lockshin, A., Giovanella, B.C., De Ipolyi, P.D., Williams Jr.,
L.J., Mendoza, J.T., Yim, S.O. and Stehlin Jr., J.S. (1985) Cancer
Res. 45, 345^350.
[17] Danen, E.H., ten Berge, P.J., van Muijen, G.N., Jager, M.J. and
Ruiter, D.J. (1996) Melanoma Res. 6, 31^35.
[18] Luyten, G.P., Naus, N.C., Mooy, C.M., Hagemeijer, A., Kan
Mitchell, J., Van Drunen, E., Vuzevski, V., De Jong, P.T. and
Luider, T.M. (1996) Int. J. Cancer 66, 380^387.
[19] Juhasz, I., Albelda, S.M., Elder, D.E., Murphy, G.F., Adachi,
K., Herlyn, D., Valyi-Nagy, I.T. and Herlyn, M. (1993) Am. J.
Pathol. 143, 528^537.
[20] Scheibenbogen, C., Keilholz, U., Meuer, S., Dengler, T., Tilgen,
W. and Hunstein, W. (1993) Int. J. Cancer 54, 494^498.
[21] Verbeek, M.M., Otte Holler, I., Wesseling, P., Ruiter, D.J. and
de Waal, R.M. (1994) Am. J. Pathol. 144, 372^382.
[22] Danen, E.H., Jansen, K.F., Klein, C.E., Smit, N.P., Ruiter, D.J.
and van Muijen, G.N. (1996) Eur. J. Cell Biol. 70, 69^75.
[23] Bauer, D., Muller, H., Reich, J., Riedel, H., Ahrenkiel, V., War-
thoe, P. and Strauss, M. (1993) Nucleic Acids Res. 21, 4272^
4280.
[24] Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) Molecular
Cloning: A Laboratory Manual, 2nd edn., Cold Spring Harbor
Laboratory Press, Cold Spring Harbor, NY.
[25] Altschul, S.F., Madden, T.L., Scha¡er, A.A., Zhang, J., Zhang,
Z., Miller, W. and Lipman, D.J. (1997) Nucleic Acids Res. 25,
3389^3402.
[26] Geurts van Kessel, A.H., Tetteroo, P.A., von dem Borne, A.E.,
Hagemeijer, A. and Bootsma, D. (1983) Proc. Natl. Acad. Sci.
USA 80, 3748^3752.
[27] Aust, G., Eichler, W., Laue, S., Lehmann, I., Heldin, N.E., Lotz,
O., Scherbaum, W.A., Dralle, H. and Hoang Vu, C. (1997) Can-
cer Res. 57, 1798^1806.
[28] Nagase, T., Ishikawa, K., Nakajima, D., Ohira, M., Seki, N.,
Miyajima, N., Tanaka, A., Kotani, H., Nomura, N. and Ohara,
O. (1997) DNA Res. 4, 141^150.
[29] Gorn, A.H., Lin, H.Y., Yamin, M., Auron, P.E., Flannery,
M.R., Tapp, D.R., Manning, C.A., Lodish, H.F., Krane, S.M.
and Goldring, S.R. (1992) J. Clin. Invest. 90, 1726^1735.
[30] Jiang, S. and Ulrich, C. (1995) Biochem. Biophys. Res. Commun.
207, 883^890.
[31] Osterho¡, C., Ivell, R. and Kirchho¡, C. (1997) DNA Cell Biol.
16, 379^389.
[32] Lelianova, V.G., Davletov, B.A., Sterling, A., Rahman, M.A.,
Grishin, E.V., Totty, N.F. and Ushkaryov, Y.A. (1997) J. Biol.
Chem. 272, 21504^21508.
[33] Nagase, T., Ishikawa, K., Suyama, M., Kikuno, R., Miyajima,
N., Tanaka, A., Kotani, H., Nomura, N. and Ohara, O. (1998)
DNA Res. 5, 277^286.
[34] Nishimori, H., Shiratsuchi, T., Urano, T., Kimura, Y., Kiyono,
K., Tatsumi, K., Yoshida, S., Ono, M., Kuwano, M. and Naka-
mura, Y. et al. (1997) Oncogene 15, 2145^2150.
[35] Shiratsuchi, T., Nishimori, H., Ichise, H., Nakamura, Y. and
Tokino, T. (1997) Cytogenet. Cell Genet. 79, 103^108.
[36] Wilson, R., Ainscough, R., Anderson, K., Baynes, C., Berks, M.,
Bon¢eld, J., Burton, J., Connell, M., Copsey, T. and Cooper, J.
et al. (1994) Nature 368, 32^38.
[37] Hart, A.C., Harrison, S.D., Van Vactor Jr., D.L., Rubin, G.M.
and Zipursky, S.L. (1993) Proc. Natl. Acad. Sci. USA 90, 5047^
5051.
[38] Tensen, C.P., Van Kesteren, E.R., Planta, R.J., Cox, K.J., Burke,
J.F., van Heerikhuizen, H. and Vreugdenhil, E. (1994) Proc.
Natl. Acad. Sci. USA 91, 4816^4820.
[39] Hamann, J., Eichler, W., Hamann, D., Kerstens, H.M., Pod-
dighe, P.J., Hoovers, J.M., Hartmann, E., Strauss, M. and van
Lier, R.A. (1995) J. Immunol. 155, 1942^1950.
[40] Baud, V., Chissoe, S.L., Viegas Pequignot, E., Diriong, S.,
N’Guyen, V.C., Roe, B.A. and Lipinski, M. (1995) Genomics
26, 334^344.
[41] Hadjantonakis, A., Sheward, W.J., Harmar, A.J., de Galan, L.,
Hoovers, J.M. and Little, P.F. (1997) Genomics 45, 97^104.
[42] Mohrenweiser, H., Olsen, A., Archibald, A., Beattie, C., Bur-
meister, M., Lamerdin, J., Lennon, G., Stewart, E., Stubbs, L.
and Weber, J.L. et al. (1996) Cytogenet. Cell Genet. 74, 161^186.
[43] McKnight, A.J. and Gordon, S. (1998) J. Leukocyte Biol. 63,
271^280.
[44] von Heijne, G. (1983) Eur. J. Biochem. 133, 17^21.
[45] Probst, W.C., Snyder, L.A., Schuster, D.I., Brosius, J. and Seal-
fon, S.C. (1992) DNA Cell Biol. 11, 1^20.
[46] van Lier, R.A., Eichler, W. and Hamann, J. (1996) Immunol.
Lett. 54, 185^187.
[47] Hamann, J., Hartmann, E. and van Lier, R.A. (1996) Genomics
32, 144^147.
[48] Watson, S. and Arkinstall, S. (1994) The G-protein Linked Re-
ceptor Facts Book, Academic Press, Londen.
[49] Davletov, B.A., Meunier, F.A., Ashton, A.C., Matsushita, H.,
Hirst, W.D., Lelianova, V.G., Wilkin, G.P., Dolly, J.O. and Ush-
karyov, Y.A. (1998) EMBO J. 17, 3909^3920.
[50] Hamann, J., Vogel, B., van Schijndel, G.M. and van Lier, R.A.
(1996) J. Exp. Med. 184, 1185^1189.
FEBS 21698 15-3-99
A.J.W. Zendman et al./FEBS Letters 446 (1999) 292^298298
